Fig. 5: SNAGs increase activation markers of CD8+ T cells.
From: Engineering synthetic agonists for targeted activation of Notch signaling
PBMCs were used to isolate naïve CD8+ T cells that were treated with 100 nM DeltaMAX–Fc, PDL1-SNAGFc or HER2-SNAGFc or not treated (control) in the presence of PDL1+ MDA-MB-231 cells or HER2+ SK-BR-3 cells, followed by human CD3 and CD28 stimulation for 48 h before isolation. a, Schematic depicting a SNAG engaging the target biomarkers expressed on a tumor cell and Notch receptors of a CD8+ T cell. b,c, The first bar chart shows the percentage of CD8+ and GrB+ T cells and subsequent three bar charts show the relative mRNA levels for GZMB, IFNG and HES4 normalized to the control; each bar represents the fold change. Error bars represent the s.d. of n = 3 technical replicates, with the P value determined using a two-sided Student’s t-test shown above each comparison.
